Related Experiment Video

Updated: Dec 26, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.4K

Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical

Qiufen Guo1,2, Yawen Sun3, Enqi Kong2

  • 1Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan.

Medicine
|March 17, 2020
PubMed
Abstract

Insights

Apatinib combined with chemotherapy or CCBT significantly improved progression-free survival and response rates in advanced cervical cancer patients. While side effects like hypertension were more common, they were manageable, indicating apatinib

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Apatinib mesylate is a targeted therapy inhibiting VEGFR-2, showing efficacy in various solid tumors.
  • Cervical cancer, particularly recurrent and advanced stages, presents significant treatment challenges.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of apatinib combined with chemotherapy and concurrent chemo-brachytherapy (CCBT) in patients with recurrent and advanced cervical cancer.
  • To compare outcomes between apatinib-treated patients and a control group receiving standard treatments.

Main Methods:

  • A randomized controlled trial involving 52 patients with International Federation of Gynecology and Obstetrics stage IVB cervical cancer.
  • Patients received either apatinib plus chemotherapy/CCBT or chemotherapy/CCBT alone.

Main Results:

  • The apatinib group demonstrated significantly prolonged progression-free survival (10.1 vs. 6.4 months) and a higher objective response rate (64.3% vs. 33.3%).
  • Increased incidence of proteinuria, hand-foot syndrome, mucositis, and hypertension was observed in the apatinib group, but other side effects were not significantly aggravated.

Conclusions:

  • Apatinib combination therapy shows promising efficacy in cervical cancer, improving response rates and progression-free survival.
  • Apatinib offers a manageable safety profile for advanced cervical cancer treatment.

More Related Videos

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

675
Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.8K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
471
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
528
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K